Article Text

Download PDFPDF

Randomised controlled trial
Dihydroartemisinin–piperaquine holds promise as an option for malaria prevention in pregnancy
  1. Jenny Hill,
  2. Feiko O ter Kuile
  1. Liverpool School of Tropical Medicine, Liverpool, UK
  1. Correspondence to : Dr Jenny Hill, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L37 3QA, UK; jenny.hill{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Malaria in pregnancy has devastating consequences for mother and fetus. WHO recommends intermittent preventive treatment in pregnancy (IPTp) with treatment doses of an efficacious antimalarial during the second and third trimesters of pregnancy at predefined intervals. Sulfadoxine–pyrimethamine is currently recommended, but high-level parasite resistance threatens its efficacy. Recent trials showed that amodiaquine, mefloquine and chloroquine–azithromycin are not suitable alternatives due to poor tolerability. This trial by Kakuru et al evaluated the artemisinin-based combination therapy (ACT), dihydroartemisinin–piperaquine, for IPTp. Dihydroartemisinin–piperaquine is already recommended by WHO for treatment of malaria in the second and third trimesters. A recent comparison of four ACTs for treatment of malaria in pregnancy in Africa showed that dihydroartemisinin–piperaquine had …

View Full Text